



FW

PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/801,623	
	Filing Date	March 15, 2004	
	First Named Inventor	Chong-Sheng YUAN	
	Art Unit	1651	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	10	Attorney Docket Number	466992001400

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-1449 (3 pages + duplicate) 47 References Return Postcard
<div>Remarks</div> <p>CUSTOMER NO. 25225</p>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP Peng Chen - 43,543
Signature	
Date	September 23, 2004


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: 9-23-04	Signature: (Rhea Amid)



PATENT
Docket No. 466992001400

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on September 23, 2004.


Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Chong-Sheng YUAN et al.

Serial No.: 10/801,623

Filing Date: March 15, 2004

For: METHODS AND COMPOSITIONS FOR
ASSAYING HOMOCYSTEINE

Examiner: Not Yet Assigned

Group Art Unit: 1651

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are not submitted. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does

not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.


In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **466992001400**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: September 23, 2004

Respectfully submitted,

By: 
Peng Chen
Registration No. 43,543

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5117
Facsimile: (858) 720-5125

Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 466992001400	Application Number: 10/801,623
	Applicant: Chong-Sheng YUAN et al.	
	Filing Date: March 15, 2004	Group Art Unit: 1651
	Mailing Date September <u>13</u> , 2004	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	05/1997	5,631,127	Sundrehagen	435	004	
	2.	10/1998	5,827,645	Sundrehagen	435	004	
	3.	12/1998	5,854,023	Hillman et al.	435	069.1	
	4.	01/1999	5,861,294	Cowart et al.	435	194	
	5.	03/1999	5,885,767	Rozzell, Jr.	435	004	
	6.	09/1999	5,958,717	Sundrehagen	435	018	
	7.	05/2000	6,063,581	Sundrehagen	435	007.1	
	8.	04/2002	6,376,210	Yuan	435	018	
	9.	08/2002	6,436,658	Seman	435	018	
	10.	12/2003	6,664,073	Kawasaki et al.	435	025	
	11.	02/2004	6,686,172	Matsuyama et al.	435	018	
	12.	08/2002	2002/0119507	Kishimoto et al.	435	026	12/03/2001

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	13.	07/2003	WO 03/060478	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	14.	Araki, et al., J. Chromatog., <u>422</u> :43-52 (1987)
	15.	Ballal, et al., Cleveland Clinic Journal of Medicine, <u>64</u> :543-549 (1997)
	16.	Boers, et al., J. Inher. Metab. Dis., <u>20</u> :301-306 (1997)
	17.	Boushey, et al., JAMA, <u>274</u> :1049-1057 (1995)
	18.	Cornell and Riscoe, Biochim. Biophys. Acta, <u>1396</u> (1):8-14 (1998)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number: 466992001400	Application Number: 10/801,623	
		Applicant: <div style="text-align: center;">Chong-Sheng YUAN et al.</div>		
		Filing Date: March 15, 2004	Group Art Unit: 1651	
		Mailing Date September <u>23</u> , 2004		
	19.	Coulter-Karis and Hershfield, Ann. Hum. Genet., <u>53</u> (2):169-175 (1989)		
	20.	Diaz-Arrastia, et al., Arch. Neurol., <u>55</u> :1407-1408 (1998)		
	21.	Ducloux, et al., Nephrol. Dial. Transplant, <u>13</u> :2890-2893 (1998)		
	22.	Foody, et al., Clinician Reviews, <u>8</u> :203-210 (1998)		
	23.	Frantzen, et al., Clinical Chemistry 44:2, 311-316 (1998)		
	24.	Gore, Int. J. Biochem., <u>13</u> (8):879-86 (1981)		
	25.	Hornberger, et al., American J. of Public Health, <u>88</u> :61-67 (1998)		
	26.	Jacobsen, et al., Clin. Chem., <u>44</u> :2238-2239 (1998)		
	27.	Lai, et al., Mol. Cell. Biol., <u>17</u> (5):2413-24 (1997)		
	28.	Mansoor, et al., Anal. Biochem., <u>200</u> :218-229 (1992)		
	29.	Matsuyama, et al., Clinical Chemistry, <u>47</u> :2155-2156 (2001)		
	30.	McNally et al., Biochem. Biophys. Res. Commun. 231:645-650 (1997)		
	31.	Moghadasian, et al., Arch. Intern. Med., <u>157</u> :2299-2307 (1997)		
	32.	Perez-de la Mora et al., Anal. Biochem., <u>180</u> (2):248-52 (1989)		
	33.	Perry, "Homocystinuria" in Nyhan W.L. ed., Heritable disorders of amino acid metabolism. New York, John Wiley & Sons, pp. 395-428 (1974)		
	34.	Refsum, et al., Annu. Rev. Medicine, <u>49</u> :31-62 (1998)		
	35.	Saksela and Raivio, Biochem. J., <u>315</u> (1):235-9 (1996)		
	36.	Scott, et al., "The etiology of neural tube defects" in Graham, I., Refsum, H., Rosenberg, I.H., and Ureland P.M. ed. "Homocysteine metabolism: from basic science to clinical medicine" Kluwer Academic Publishers, Boston, pp. 133-136 (1995)		
	37.	Shapiro, Biochim. Biophys. Acta. <u>29</u> :405-9 (1958)		
	38.	Shapiro et al., J. Biol. Chem., <u>239</u> (5):1551-6 (1964)		
	39.	Sigma-Aldrich catalog No. A5168		
	40.	Sigma-Aldrich catalog No. 01898		
	41.	Sigma-Aldrich catalog No. A9876		
	42.	Sigma-Aldrich catalog No. A1030		
	43.	Sigma-Aldrich catalog No. BCR647		
	44.	Sigma-Aldrich catalog No. 59023		
	45.	Sigma-Aldrich catalog No. 61311		
	46.	Sigma-Aldrich catalog No. 61306		
EXAMINER:		DATE CONSIDERED:		
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.				

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number: 466992001400	Application Number: 10/801,623
	Applicant: Chong-Sheng YUAN et al.	
	Filing Date: March 15, 2004	Group Art Unit: 1651
	Mailing Date September <u>23</u> 2004	

	47.	Sigma-Aldrich catalog No. K4388
	48.	Sigma-Aldrich catalog No. P1903
	49.	Sigma-Aldrich catalog No. P5788
	50.	Sigma-Aldrich catalog No. 83330
	51.	Singh et al., Eur. J. Biochem. 241:564-571 (1996)
	52.	Stabler, et al., J. Clin. Invest., <u>81</u> :466-474 (1988)
	53.	Stehouwer, et al., Kidney International, <u>55</u> :308-314 (1999)
	54.	Stein, et al., Arch. Intern. Med., <u>158</u> :1301-1306 (1998)
	55.	Tan et al., Clinical Chemistry, <u>49</u> :1029-1030 (2003)
	56.	Thanbichler et al., J. Bacteriol., <u>181</u> (2):662-5 (1999)
	57.	Thomas et al., J Biol. Chem., <u>275</u> (52):40718-24 (2000)
	58.	Ueland, et al., J. Lab. Clin. Med., <u>114</u> :473-501 (1989)
	59.	Ueland, et al., Clin. Chem., <u>39</u> :1764-1779 (1993)

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	